Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Invest Ophthalmol Vis Sci ; 57(3): 971-8, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26962693

RESUMO

PURPOSE: To investigate the effects of paclitaxel associated with lipid nanoemulsions (LDE-PTX) on postoperative scarring in rabbits undergoing trabeculectomy. METHODS: Thirty-four rabbits that underwent trabeculectomy were allocated to four groups: LDE-PTX/SC (n = 9), treated with LDE-PTX (1.5 mg, intraoperative subconjunctival injection); LDE-PTX/IV (n = 9), treated with LDE-PTX (4 mg/kg per day intravenously) at the end of the surgery and once per week for 3 weeks; MMC (n = 9), treated with intraoperative 0.4 mg/mL mitomycin-C for 3 minutes; and control group (CTL, n = 7), without treatment. Bleb characteristics and IOP were evaluated over 4 weeks. Animals were killed on day 28. Histologic analyses were performed to assess the amount of scarring and toxicity to the conjunctiva and ciliary body. RESULTS: Groups were similar with respect to IOP and anterior chamber depth during the 28-day observation period. The LDE-PTX/SC, LDE-PTX/IV, and MMC groups showed greater bleb height than CTL on days 14 and 21 (P < 0.001). The LDE-PTX/SC, LDE-PTX/IV, and MMC groups showed longer bleb survival time than CTL (P < 0.001). The LDE-PTX/SC, LDE-PTX/IV, and MMC groups were equally effective in reducing fibrosis (P < 0.001), number of blood vessels (P < 0.001), and chronic inflammatory cells (P < 0.01) at the surgical site. However, LDE-PTX/SC and LDE-PTX/IV treatments had lower conjunctival (P < 0.001) and ciliary body toxicity (P < 0.01), compared with MMC. CONCLUSIONS: The LDE-PTX/SC was effective in reducing the scarring process following trabeculectomy to the same extent as MMC, but with considerably less toxicity to the conjunctiva and ciliary body. The LDE-PTX/IV was somewhat less effective than LDE-PTX/SC or MMC, but could have potential as a postoperative adjuvant treatment. Therefore, the LDE-PTX preparation in both administration routes may offer promising options for wound-healing modulation in the surgical treatment of glaucoma.


Assuntos
Cicatriz/prevenção & controle , Glaucoma/cirurgia , Nanopartículas/administração & dosagem , Paclitaxel/administração & dosagem , Complicações Pós-Operatórias/prevenção & controle , Trabeculectomia/efeitos adversos , Animais , Antineoplásicos Fitogênicos/administração & dosagem , Cicatriz/diagnóstico , Cicatriz/etiologia , Túnica Conjuntiva , Modelos Animais de Doenças , Portadores de Fármacos , Seguimentos , Glaucoma/fisiopatologia , Injeções , Pressão Intraocular , Lipídeos , Masculino , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/etiologia , Coelhos
2.
Clin Ophthalmol ; 8: 1259-61, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25061273

RESUMO

Ectopic cilia are rare in humans. We report a 6-year-old girl with typical characteristics of ectopic cilia as described in the rare cases reported in the literature, in association with cutaneous lesions that appeared to be hypochromic nevi. This framework could be a different clinical presentation of ectopic cilia.

3.
Cornea ; 32(4): 517-9, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23238395

RESUMO

PURPOSE: IgG4-related sclerosing disease is a new clinicopathologic systemic entity, which can involve ocular adnexal structures, such as lacrimal glands and orbital tissues. However, this entity seems to display a more diffuse, frequently bilateral, pattern in such cases. Conjunctival involvement has not been reported in this disease. METHODS: We report the case of a 67-year-old woman with left upper palpebral mass for 5 months. A biopsy was performed, and the patient underwent systemic evaluation for IgG4-related disease. RESULTS: The clinicopathologic study revealed intense lymphoplasmacytic and sclerosing inflammation, with IgG4-positive plasma cells and an IgG4:IgG ratio >40%. The conjunctiva was also involved, which was different from previous studies. The only abnormality was hyperglycemia at 180 mg/dL (reference range, 70-99 mg/dL) and a raised glycosylated hemoglobin at 7.8%. Serum IgG and IgG4 levels were normal. CONCLUSIONS: Our case presented an unusual framework of ocular adnexal IgG4-related inflammation, with a more benign and restricted palpebral manifestation involving the conjunctiva.


Assuntos
Doenças Palpebrais/imunologia , Imunoglobulina G/análise , Idoso , Túnica Conjuntiva/imunologia , Túnica Conjuntiva/patologia , Doenças Palpebrais/patologia , Feminino , Humanos , Esclerose/imunologia , Esclerose/patologia
4.
Pharmacology ; 89(1-2): 22-8, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22236644

RESUMO

The aim of the present study was to investigate the mechanisms underlying the endogenous control of nociception at a peripheral level during inflammation. Using a pharmacological approach and the rat paw pressure test, we assessed the effect of an intraplantar injection of naloxone, an opioid receptor antagonist, and bestatin, an aminopeptidase inhibitor, on hyperalgesia induced by carrageenan, which mimics an inflammatory process, or prostaglandin E(2) (PGE(2)), which directly sensitizes nociceptors. Naloxone induced a significant and dose-dependent (25, 50 or 100 µg) increase in carrageenan-induced hyperalgesia, but not PGE(2)-induced hyperalgesia. Bestatin (400 µg/paw) significantly counteracted carrageenan-induced hyperalgesia, inducing an increase in the nociceptive threshold compared to control, but it did not modify hyperalgesia induced by PGE(2) injection into the rat paw. Positive ß-endorphin immunoreactivity was increased in paw inflammation induced by carrageenan in comparison with the control group. However, PGE(2) did not significantly alter the immunostained area. These results provide evidence for activation of the endogenous opioidergic system during inflammation and indicate that this system regulates hyperalgesia through a negative feedback mechanism, modulating it at a peripheral level.


Assuntos
Inflamação/metabolismo , Peptídeos Opioides/fisiologia , Limiar da Dor/fisiologia , beta-Endorfina/metabolismo , Animais , Carragenina/efeitos adversos , Carragenina/agonistas , Carragenina/antagonistas & inibidores , Dinoprostona/efeitos adversos , Relação Dose-Resposta a Droga , Hiperalgesia/induzido quimicamente , Leucina/análogos & derivados , Leucina/farmacologia , Masculino , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Limiar da Dor/efeitos dos fármacos , Inibidores de Proteases/farmacologia , Ratos , Ratos Wistar
5.
J Pediatr (Rio J) ; 85(1): 72-9, 2009.
Artigo em Inglês, Português | MEDLINE | ID: mdl-19198739

RESUMO

OBJECTIVE: To evaluate the clinical profile of newborns with congenital hypothyroidism identified by the Newborn Screening Program of the State of Minas Gerais, Brazil, between 2000 and 2006. METHODS: Analysis of factors involved in this profile, including: TSH and FT4 levels (determined by chemiluminescence, with limits of normality set at 0.3-5.0 microUI/mL and 0.8-1.8 ng/dL, respectively), age at diagnosis and age at treatment. The study sample consisted of 443 children, 55.8% were female and 95% were seen before completing 60 days of life. RESULTS: The most prevalent clinical signals were: umbilical hernia (51%), enlarged anterior fontanel (50.3%), and open posterior fontanel (47.2%). Hypotonia, macroglossia and feeding difficulties were the clinical signs most frequently associated with the biochemical severity of the disease. A delay in bone age was present in 32.1% of the children at diagnosis. The median of serum TSH and FT4 was 120 microUI/mL and 0.62 ng/dL, respectively. The median age at start of treatment was 28 days. CONCLUSION: There are some early clinical signs that suggest a diagnosis of congenital hypothyroidism. Therefore, when presented with a child exhibiting these signs, serum TSH and FT4 should be assayed in order to confirm or rule out the disease, irrespective of the result of screening. Age at start of treatment remains high, but strategies are being implemented to reduce it.


Assuntos
Hipotireoidismo Congênito/diagnóstico , Determinação da Idade pelo Esqueleto , Biomarcadores/sangue , Brasil/epidemiologia , Hipotireoidismo Congênito/sangue , Hipotireoidismo Congênito/complicações , Hipotireoidismo Congênito/epidemiologia , Fontanelas Cranianas/patologia , Feminino , Hérnia Umbilical/diagnóstico , Hérnia Umbilical/epidemiologia , Humanos , Recém-Nascido , Masculino , Triagem Neonatal , Estatísticas não Paramétricas , Tireotropina/sangue , Tiroxina/sangue , Fatores de Tempo
6.
J. pediatr. (Rio J.) ; J. pediatr. (Rio J.);85(1): 72-79, jan.-fev. 2009. ilus, tab
Artigo em Inglês, Português | LILACS | ID: lil-507707

RESUMO

OBJETIVO: Avaliar o perfil clínico de recém-nascidos com hipotireoidismo congênito identificados pelo Programa Estadual de Triagem Neonatal de Minas Gerais entre 2000 e 2006. MÉTODOS: A frequência das manifestações clínicas de hipotireoidismo congênito foi analisada em relação aos níveis de hormônio estimulante da tireoide T4L (determinados por quimioluminescência, valores de referência de 0,3 a 5,0 µUI/mL e 0,8 a 1,8 ng/dL, respectivamente) e idades ao diagnóstico e tratamento. Estudou-se 443 crianças, sendo 55,8 por cento do sexo feminino e 95 por cento delas com menos 60 dias de vida. RESULTADOS: Os sinais clínicos mais prevalentes foram: hérnia umbilical (51 por cento), fontanela anterior ampla (50,3 por cento) e fontanela posterior aberta (47,2 por cento). Hipotonia, macroglossia e sucção débil foram os sinais mais associados com a gravidade bioquímica da doença. Em 32,1 por cento das crianças houve atraso na idade óssea ao diagnóstico. As medianas de TSH e T4L séricos foram 120 µUI/mL e 0,62 ng/dL, respectivamente. A mediana da idade de início de tratamento foi de 28 dias. CONCLUSÃO: Existem sinais clínicos precoces que sugerem o diagnóstico de hipotireoidismo congênito. Portanto, diante de uma criança com esses sinais, devem ser avaliados TSH e T4L séricos para confirmar ou excluir a doença, independentemente do resultado do teste de triagem. A idade de início de tratamento ainda foi elevada, mas o programa vem adotando estratégias para redução da mesma.


OBJECTIVE: To evaluate the clinical profile of newborns with congenital hypothyroidism identified by the Newborn Screening Program of the State of Minas Gerais, Brazil, between 2000 and 2006. METHODS: Analysis of factors involved in this profile, including: TSH and FT4 levels (determined by chemiluminescence, with limits of normality set at 0.3-5.0 µUI/mL and 0.8-1.8 ng/dL, respectively), age at diagnosis and age at treatment. The study sample consisted of 443 children, 55.8 percent were female and 95 percent were seen before completing 60 days of life. RESULTS: The most prevalent clinical signals were: umbilical hernia (51 percent), enlarged anterior fontanel (50.3 percent), and open posterior fontanel (47.2 percent). Hypotonia, macroglossia and feeding difficulties were the clinical signs most frequently associated with the biochemical severity of the disease. A delay in bone age was present in 32.1 percent of the children at diagnosis. The median of serum TSH and FT4 was 120 µUI/mL and 0.62 ng/dL, respectively. The median age at start of treatment was 28 days. CONCLUSION: There are some early clinical signs that suggest a diagnosis of congenital hypothyroidism. Therefore, when presented with a child exhibiting these signs, serum TSH and FT4 should be assayed in order to confirm or rule out the disease, irrespective of the result of screening. Age at start of treatment remains high, but strategies are being implemented to reduce it.


Assuntos
Feminino , Humanos , Recém-Nascido , Masculino , Hipotireoidismo Congênito/diagnóstico , Determinação da Idade pelo Esqueleto , Biomarcadores/sangue , Brasil/epidemiologia , Hipotireoidismo Congênito/sangue , Hipotireoidismo Congênito/complicações , Hipotireoidismo Congênito/epidemiologia , Fontanelas Cranianas/patologia , Hérnia Umbilical/diagnóstico , Hérnia Umbilical/epidemiologia , Triagem Neonatal , Estatísticas não Paramétricas , Fatores de Tempo , Tireotropina/sangue , Tiroxina/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA